Matthew A. Cavender

10.9k total citations · 6 hit papers
86 papers, 6.7k citations indexed

About

Matthew A. Cavender is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Matthew A. Cavender has authored 86 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Cardiology and Cardiovascular Medicine, 31 papers in Surgery and 25 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Matthew A. Cavender's work include Diabetes Treatment and Management (24 papers), Acute Myocardial Infarction Research (22 papers) and Antiplatelet Therapy and Cardiovascular Diseases (18 papers). Matthew A. Cavender is often cited by papers focused on Diabetes Treatment and Management (24 papers), Acute Myocardial Infarction Research (22 papers) and Antiplatelet Therapy and Cardiovascular Diseases (18 papers). Matthew A. Cavender collaborates with scholars based in United States, United Kingdom and Netherlands. Matthew A. Cavender's co-authors include Deepak L. Bhatt, Philippe Gabríel Steg, Benjamin M. Scirica, Jacob A. Udell, Darren K. McGuire, Eugene Braunwald, Itamar Raz, Ofri Mosenzon, Boaz Hirshberg and Jaime A. Davidson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Matthew A. Cavender

83 papers receiving 6.5k citations

Hit Papers

Saxagliptin and Cardiovascular Outcomes in Patients with ... 2013 2026 2017 2021 2013 2017 2014 2017 2015 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
    2013 2.5k citations Benjamin M. Scirica, Deepak L. Bhatt et al. New England Journal of Medicine profile →
  2. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs
    2017 604 citations Mikhail Kosiborod, Matthew A. Cavender et al. Circulation profile →
  3. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
    2014 545 citations Benjamin M. Scirica, Eugene Braunwald et al. Circulation profile →
  4. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
    2017 431 citations Matthew A. Cavender et al. Circulation profile →
  5. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death
    2015 364 citations Matthew A. Cavender, Philippe Gabríel Steg et al. Circulation profile →
  6. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
    2025 89 citations Darren K. McGuire, Nikolaus Marx et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthew A. Cavender United States 28 4.7k 2.3k 2.1k 2.0k 684 86 6.7k
Stuart Kupfer United States 27 4.0k 0.8× 2.3k 1.0× 1.3k 0.6× 1.6k 0.8× 505 0.7× 82 5.6k
Jennifer B. Green United States 31 3.6k 0.8× 1.5k 0.6× 1.3k 0.6× 1.4k 0.7× 474 0.7× 91 5.0k
Jaime A. Davidson United States 35 6.6k 1.4× 1.1k 0.5× 2.7k 1.3× 2.4k 1.2× 784 1.1× 98 8.2k
Samuel S. Engel United States 37 3.7k 0.8× 743 0.3× 1.2k 0.6× 1.4k 0.7× 652 1.0× 127 5.1k
KyungAh Im United States 24 3.5k 0.7× 1.5k 0.7× 1.5k 0.7× 1.4k 0.7× 243 0.4× 47 4.7k
Richard M. Bergenstal United States 15 6.6k 1.4× 1.5k 0.6× 2.2k 1.0× 2.6k 1.3× 484 0.7× 29 7.6k
Marcus Thuresson Sweden 37 2.3k 0.5× 1.4k 0.6× 1.4k 0.7× 949 0.5× 421 0.6× 123 4.9k
Michael Szarek United States 34 3.3k 0.7× 2.4k 1.0× 3.9k 1.9× 1.0k 0.5× 352 0.5× 127 7.4k
Boaz Hirshberg United States 41 6.2k 1.3× 1.1k 0.5× 3.5k 1.7× 2.7k 1.4× 1.2k 1.8× 118 8.7k
Avivit Cahn Israel 29 7.7k 1.6× 2.0k 0.9× 3.0k 1.4× 3.1k 1.6× 292 0.4× 113 9.3k

Countries citing papers authored by Matthew A. Cavender

Since Specialization
Citations

This map shows the geographic impact of Matthew A. Cavender's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew A. Cavender with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew A. Cavender more than expected).

Fields of papers citing papers by Matthew A. Cavender

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew A. Cavender. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew A. Cavender. The network helps show where Matthew A. Cavender may publish in the future.

Co-authorship network of co-authors of Matthew A. Cavender

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew A. Cavender. A scholar is included among the top collaborators of Matthew A. Cavender based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew A. Cavender. Matthew A. Cavender is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McGuire, Darren K., Nikolaus Marx, Sharon L. Mulvagh, et al.. (2025). Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. New England Journal of Medicine. 392(20). 2001–2012. 89 indexed citations breakdown →
2.
3.
Arora, Sameer, Patricia P. Chang, Muthiah Vaduganathan, et al.. (2023). Epidemiology and Outcomes of Aortic Stenosis in Acute Decompensated Heart Failure: The ARIC Study. Circulation Heart Failure. 16(3). e009653–e009653. 1 indexed citations
4.
5.
Wang, Yongfei, Karl E. Minges, Robert L. McNamara, et al.. (2021). Predicting In-Hospital Mortality in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 78(3). 216–229. 42 indexed citations
6.
Wittbrodt, Eric, Narinder Bhalla, Karolina Andersson Sundell, et al.. (2020). Assessment of the high risk and unmet need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource utilization, cost and burden of illness in the Diabetes Collaborative Registry. Endocrinology Diabetes & Metabolism. 3(3). e00133–e00133. 8 indexed citations
7.
Clarke, Megan M., et al.. (2019). Loperamide overdose causing torsades de pointes and requiring Impella temporary mechanical support: a case report. European Heart Journal - Case Reports. 3(4). 1–6. 7 indexed citations
8.
Arora, Sameer, Sreekanth Vemulapalli, Amanda Stebbins, et al.. (2019). The Prevalence and Impact of Atrial Fibrillation on 1-Year Outcomes in Patients Undergoing Transcatheter Mitral Valve Repair. JACC: Cardiovascular Interventions. 12(6). 569–578. 32 indexed citations
9.
Cavender, Matthew A., et al.. (2019). Hypertension Treatment in Diabetes. Heart Failure Clinics. 15(4). 551–563. 3 indexed citations
10.
Cannon, Christopher P., Steven Hearne, Sara Jaffer, et al.. (2018). Abstract 14202: The Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation (BOAT-AF) Study: A Prospective, Multicenter Study Evaluating Perspectives on Use of Oral Anticoagulation Using a Patient Survey and Clinical Review by the Treating Physician Among Patients Not Currently Treated With Oral Anticoagulation. Circulation. 1 indexed citations
11.
Arora, Sameer, Sreekanth Vemulapalli, Amanda Stebbins, et al.. (2018). ATRIAL FIBRILLATION IS ASSOCIATED WITH HIGHER RATES OF DEATH AND HEART FAILURE HOSPITALIZATIONS IN PATIENTS UNDERGOING MITRACLIP: OUTCOMES FROM THE TVT REGISTRY. Journal of the American College of Cardiology. 71(11). A1382–A1382. 1 indexed citations
12.
Kosiborod, Mikhail, Matthew A. Cavender, Alex Z. Fu, et al.. (2017). Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs. Circulation. 136(3). 249–259. 604 indexed citations breakdown →
13.
Lee, David W., Prashant Kaul, George A. Stouffer, et al.. (2017). Abstract 19292: Cardiovascular Secondary Prevention Therapies are Underprescribed in Patients With Peripheral Artery Disease: Findings From the NCDR PINNACLE Registry. Circulation. 1 indexed citations
14.
Cavender, Matthew A., Robert A. Harrington, Gregg W. Stone, et al.. (2017). ISCHEMIC EVENTS OCCUR EARLY IN PATIENTS UNDERGOING PCI AND ARE REDUCED WITH CANGRELOR: FINDINGS FROM CHAMPION PHOENIX. Journal of the American College of Cardiology. 69(11). 25–25. 3 indexed citations
15.
Cavender, Matthew A., Deepak L. Bhatt, Gregg W. Stone, et al.. (2015). CANGRELOR IN ELDERLY PATIENTS UNDERGOING PCI: FINDINGS FROM CHAMPION-PHOENIX. Journal of the American College of Cardiology. 65(10). A1773–A1773. 3 indexed citations
16.
Udell, Jacob A., Matthew A. Cavender, Deepak L. Bhatt, et al.. (2015). Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. The Lancet Diabetes & Endocrinology. 3(5). 356–366. 201 indexed citations
17.
Cavender, Matthew A., Eugene Braunwald, C. Michael Gibson, et al.. (2013). RIVAROXABAN REDUCES SPONTANEOUS AND LARGE MYOCARDIAL INFARCTIONS: FINDINGS FROM THE ATLAS ACS 2 – TIMI 51 TRIAL. Journal of the American College of Cardiology. 61(10). E3–E3. 3 indexed citations
18.
Rassi, Andrew N., Matthew A. Cavender, Gregg C. Fonarow, et al.. (2012). Temporal Trends and Predictors in the Use of Aldosterone Antagonists Post-Acute Myocardial Infarction. Journal of the American College of Cardiology. 61(1). 35–40. 35 indexed citations
19.
Wang, Tracy, Lisa A. Kaltenbach, Deepak L. Bhatt, et al.. (2011). LONG-TERM MORTALITY ASSOCIATED WITH MULTIVESSEL VERSUS CULPRIT VESSEL ONLY PERCUTANEOUS CORONARY INTERVENTION FOR PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: INSIGHTS FROM THE NATIONAL CARDIOVASCULAR CATHPCI DATA REGISTRY. Journal of the American College of Cardiology. 57(14). E914–E914. 1 indexed citations
20.
Cavender, Matthew A. & Sunil V. Rao. (2010). Bleeding associated with current therapies for acute coronary syndrome: What are the mechanisms?. Journal of Thrombosis and Thrombolysis. 30(3). 332–339. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stuart Kupfer Breakdown of academic impact, for papers by Jennifer B. Green Breakdown of academic impact, for papers by Jaime A. Davidson Breakdown of academic impact, for papers by Samuel S. Engel Breakdown of academic impact, for papers by KyungAh Im Breakdown of academic impact, for papers by Richard M. Bergenstal Breakdown of academic impact, for papers by Marcus Thuresson Breakdown of academic impact, for papers by Michael Szarek Breakdown of academic impact, for papers by Boaz Hirshberg Breakdown of academic impact, for papers by Avivit Cahn
Rankless by CCL
2026